Duane  Nash net worth and biography

Duane Nash Biography and Net Worth

Chairman of Immunic
Duane Nash, M.D., J.D., M.B.A, joined Immunic’s board as its chairman in 2019. Since April 2020, he has temporarily assumed the role of Executive Chairman.
From 2012 to 2019, Dr. Nash served in various leadership roles at Vital Therapies (Nasdaq: VTL), most recently as its Chief Executive Officer. Additional roles included Medical Director, Executive Vice President, Chief Business Officer and President. Prior to joining Vital Therapies, Dr. Nash held various positions at Wedbush PacGrowth Life Sciences, an investment bank, where he worked from 2009 to 2012, most recently as Senior Vice President in Equity Research. Before that, he was a research analyst at Pacific Growth Equities, which was acquired by Wedbush in 2009.
Dr. Nash also practiced law from 2002 to 2008, most recently at the law firm of Davis Polk & Wardwell, where he focused on intellectual property litigation and corporate matters. Dr. Nash served on the board of directors of Aerpio Pharmaceuticals (Nasdaq: ARPO) from 2012 to 2017, and Akebia Therapeutics (Nasdaq: AKBA) from 2013 to 2018.
Dr. Nash earned a B.A. in biology from Williams College, an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford. Dr. Nash completed his internship in general surgery at the University of California, San Francisco.

What is Duane Nash's net worth?

The estimated net worth of Duane Nash is at least $27,319.68 as of May 12th, 2022. Dr. Nash owns 22,032 shares of Immunic stock worth more than $27,320 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Nash may own. Additionally, Dr. Nash receives a salary of $433,400.00 as Chairman at Immunic. Learn More about Duane Nash's net worth.

How old is Duane Nash?

Dr. Nash is currently 53 years old. There are 6 older executives and no younger executives at Immunic. The oldest executive at Immunic is Dr. Andreas Muehler M.D., Ph.D., Chief Medical Officer, who is 59 years old. Learn More on Duane Nash's age.

What is Duane Nash's salary?

As the Chairman of Immunic, Inc., Dr. Nash earns $433,400.00 per year. There are 3 executives that earn more than Dr. Nash. The highest earning executive at Immunic is Dr. Daniel Vitt Ph.D., CEO, President & Director, who commands a salary of $728,400.00 per year. Learn More on Duane Nash's salary.

How do I contact Duane Nash?

The corporate mailing address for Dr. Nash and other Immunic executives is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. Immunic can also be reached via phone at (332) 255-9818 and via email at [email protected]. Learn More on Duane Nash's contact information.

Has Duane Nash been buying or selling shares of Immunic?

Duane Nash has not been actively trading shares of Immunic during the last ninety days. Most recently, on Thursday, May 12th, Duane Nash bought 10,000 shares of Immunic stock. The stock was acquired at an average cost of $5.03 per share, with a total value of $50,300.00. Following the completion of the transaction, the chairman now directly owns 22,032 shares of the company's stock, valued at $110,820.96. Learn More on Duane Nash's trading history.

Who are Immunic's active insiders?

Immunic's insider roster includes Duane Nash (Chairman), Daniel Vitt (CEO), and Glenn Whaley (Insider). Learn More on Immunic's active insiders.

Are insiders buying or selling shares of Immunic?

In the last twelve months, Immunic insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $8,750.00. The most recent insider tranaction occured on May, 15th when CFO Glenn Whaley bought 5,000 shares worth more than $8,750.00. Insiders at Immunic own 2.7% of the company. Learn More about insider trades at Immunic.

Information on this page was last updated on 5/15/2023.

Duane Nash Insider Trading History at Immunic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Buy10,000$5.03$50,300.0022,032View SEC Filing Icon  
5/12/2021Buy4,000$12.75$51,000.0014,032View SEC Filing Icon  
12/4/2019Sell4,400$6.96$30,624.0022,362View SEC Filing Icon  
See Full Table

Duane Nash Buying and Selling Activity at Immunic

This chart shows Duane Nash's buying and selling at Immunic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immunic Company Overview

Immunic logo
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.24
Low: $1.22
High: $1.29

50 Day Range

MA: $1.33
Low: $1.18
High: $1.53

2 Week Range

Now: $1.24
Low: $0.95
High: $3.11

Volume

129,677 shs

Average Volume

262,758 shs

Market Capitalization

$111.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07